ARMP
Armata Pharmaceuticals, Inc. AMEX Listed May 20, 1994$9.17
Mkt Cap $335.9M
52w Low $1.17
52.7% of range
52w High $16.34
50d MA $10.66
200d MA $6.41
P/E (TTM)
-1.9x
EV/EBITDA
-17.1x
P/B
—
Debt/Equity
-1.3x
ROE
79.5%
P/FCF
-8.7x
RSI (14)
—
ATR (14)
—
Beta
1.40
50d MA
$10.66
200d MA
$6.41
Avg Volume
47.2K
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
4503 Glencoe Avenue · Marina del Rey, CA 90292 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.19 | -0.51 | -168.4% | 8.61 | -5.8% | +8.6% | -10.5% | +2.6% | +19.2% | +3.1% | — |
| Nov 12, 2025 | AMC | -0.42 | -0.42 | +0.0% | 6.69 | -5.2% | -4.6% | +14.7% | -8.3% | +2.5% | +6.1% | — |
| Aug 12, 2025 | AMC | -0.39 | -0.32 | +17.9% | 2.46 | +3.7% | +1.6% | +1.2% | +0.8% | +2.4% | -2.7% | — |
| May 14, 2025 | AMC | -0.38 | -0.20 | +47.4% | 1.38 | +0.0% | +1.4% | -3.6% | +75.6% | -5.1% | -6.7% | — |
| Mar 20, 2025 | AMC | -0.35 | -0.23 | +34.3% | 2.01 | -1.0% | -10.9% | +2.8% | -8.7% | -1.8% | +0.0% | — |
| Nov 13, 2024 | AMC | -0.28 | -0.15 | +46.4% | 2.72 | +0.4% | -1.5% | -10.1% | -7.1% | -11.6% | +5.6% | — |
| Aug 13, 2024 | AMC | -0.52 | -0.65 | -25.0% | 2.71 | -2.6% | -10.7% | +0.8% | -7.0% | +3.1% | +1.3% | — |
| May 7, 2024 | AMC | -0.28 | -0.69 | -146.4% | 2.86 | -1.4% | -3.5% | +18.1% | -5.2% | +3.9% | -9.0% | — |
| Mar 21, 2024 | AMC | -0.35 | -0.55 | -57.1% | 3.69 | +0.8% | +1.4% | +4.5% | +3.3% | +1.5% | +2.0% | — |
| Nov 14, 2023 | AMC | -0.33 | -0.31 | +6.1% | 2.68 | +4.1% | -19.8% | -6.5% | +10.4% | -0.9% | -3.2% | — |
| Aug 14, 2023 | AMC | -0.35 | -0.28 | +20.0% | 4.16 | -1.9% | +3.4% | -6.7% | -1.7% | -9.6% | +1.4% | — |
| May 11, 2023 | AMC | -0.29 | -0.40 | -37.9% | 1.30 | +0.0% | -3.8% | +8.8% | +2.2% | -10.1% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.73 | $8.78 | +0.6% | +9.3% | +24.3% | -10.4% | +1.9% | -0.6% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.17 | -13.3% | +75.6% | -5.1% | -6.7% | -11.0% | +1.1% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.98 | +1.5% | +1.5% | -1.5% | -0.5% | +5.2% | -1.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.73 | +0.4% | -1.5% | -10.1% | -7.1% | -11.6% | +5.6% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $2.23 | -0.9% | +22.2% | -1.1% | -1.5% | -10.1% | -7.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.42 | +0.0% | +0.8% | -7.0% | +3.1% | +1.3% | -3.4% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.78 | +3.7% | +11.9% | +5.0% | -7.9% | +2.8% | +10.7% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.86 | $2.82 | -1.4% | -3.5% | +18.1% | -5.2% | +3.9% | -9.0% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.69 | $3.72 | +0.8% | +1.4% | +4.5% | +3.3% | +1.5% | +2.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.35 | $4.47 | +2.8% | -4.4% | +3.4% | -6.7% | -1.7% | -9.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.30 | $1.30 | +0.0% | -3.8% | +8.8% | +2.2% | -10.1% | +4.0% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.75 | $1.75 | +0.0% | +8.6% | -7.9% | -8.0% | +2.5% | -6.1% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.06 | $2.97 | -2.9% | -13.1% | -17.3% | -5.0% | -5.7% | -4.6% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.33 | $5.99 | +12.4% | -0.2% | -0.9% | +4.4% | -6.5% | -4.9% |
| May 15 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.98 | $2.98 | +0.1% | +4.0% | +2.9% | -1.3% | +0.3% | -2.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $2.98 | +0.1% | +4.0% | +2.9% | -1.3% | +0.3% | -2.8% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.89 | +5.1% | +0.0% | +5.5% | -2.8% | +20.2% | -3.2% |
| Mar 20 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.75 | $2.89 | +5.1% | +0.0% | +5.5% | -2.8% | +20.2% | -3.2% |
| Feb 6 | Maxim Group | Maintains | Buy → Buy | — | $3.71 | $3.84 | +3.5% | -2.7% | +10.0% | +1.8% | -1.0% | +4.2% |
| Jun 19 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $2.86 | $2.95 | +3.1% | +17.5% | -6.8% | -11.2% | +24.1% | +4.3% |
No insider trades available.
8-K · 5.02
!!! Very High
Armata Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Armata Pharmaceuticals appointed Dr. Daniel Gilmer as a director, expanding its board to strengthen governance and potentially bring specialized expertise to guide the company's pharmaceutical development strategy.
Apr 27
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Armata's advance notice bylaw deadline for shareholder proposals and nominations is approaching; investors should monitor whether meaningful governance challenges or director contests emerge before the cutoff.
Apr 2
8-K
Unknown — 8-K Filing
Armata's grant revenue in Q4 2025 suggests continued external funding for its bacteriophage program, reducing near-term cash burn concerns, though investors should monitor clinical trial progress and path to profitability.
Mar 25
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Armata Pharmaceuticals disclosed material information via 8-K filing on March 19, 2026, though specific details aren't provided—investors should review the full disclosure to assess impact on clinical progress, partnerships, or financial position.
Mar 19
8-K · 7.01
! Medium
Armata Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Armata Pharmaceuticals received FDA Qualified Infectious Disease Product designation for AP-SA02, potentially accelerating development timelines and providing regulatory advantages for this bacteremia treatment candidate.
Feb 23
Data updated apr 24, 2026 6:57pm
· Source: massive.com